E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider in China, announced that its subsidiary, Zhongrun (Fujian) Pharmaceutical Co., Ltd, intends to acquire NBL (New Zealand) Limited ("NBL Company").
NBL (New Zealand) Limited has advanced fully automatic production lines, and three main production workshops equipped with independent purification and air-conditioning systems, 10 sets of independent HVAC systems, mainly produces powders and soft capsules of fish oil, vitamins, anti-aging and other health care drugs. In order to meet the clean requirements of different production workshops and to ensure the low temperature and low humidity requirements of special production processes, all workshops comply with the dust-free standards of international ISO, New Zealand GMP, GB, and the GMP level 100,000 class dust-free workshop, which is in line with the international GMP workshop construction standards. The factory covers a total area of more than 5,000 square meters, and the area of purification workshop is more than 2,200 square meters.
Mr. Wenshan Xie, Chairman and CEO of E-Home, commented: "The proposed acquisition of NBL (New Zealand) Limited by Zhongrun (Fujian) Pharmaceutical Co., Ltd. a subsidiary of E-Home Household Services Holdings Limited is the result of the transition from service to R&D+production+service in the healthcare pharmaceutical industry and the expansion of the international market by Zhongrun (Fujian) Pharmaceutical Co. The combination of Zhongrun (Fujian) Pharmaceutical Co., Ltd. and NBL (New Zealand) Limited can create a large-scale healthcare pharmaceutical portfolio and flagship products, and build a good complementary and synergistic advantage of Chinese and international resources. This is a key step for Zhongrun (Fujian) Pharmaceutical Co., Ltd., a subsidiary of E-Home Household Services Holdings Limited, to move into the international market. It is believed that the completion of this merger and acquisition will have a significant impact on the development of Zhongrun (Fujian) Pharmaceutical Co. It is believed that the completion of the merger and acquisition will help Zhongrun (Fujian) Pharmaceutical Co., Ltd. to complete the R&D+Production+Service+Market+Performance."